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Abstract: We use a Stochastic Hybrid Automaton (SHA) model of prostate cancer evolution
under intermittent androgen suppression (IAS) to study a threshold-based policy for therapy
design. IAS is currently one of the most widely used treatments for advanced prostate cancer.
Patients undergoing IAS are submitted to cycles of treatment (in the form of androgen
deprivation) and off-treatment periods in an alternating manner. One of the main challenges
in IAS is to optimally design a therapy scheme, i.e., to determine when to discontinue and
recommence androgen suppression. The level of prostate specific antigen (PSA) in a patient’s
serum is frequently monitored to determine when the patient will be taken off therapy and
when therapy will resume. The threshold-based policy we propose is parameterized by lower
and upper PSA threshold values and is associated with a cost metric that combines clinically
relevant measures of therapy success. Using Infinitesimal Perturbation Analysis (IPA), we derive
unbiased gradient estimators of this cost metric with respect to the controllable PSA threshold
values based on actual data and show how these estimators can be used to adaptively adjust
controllable parameters so as to improve therapy outcomes based on the cost metric defined.
Keywords: stochastic hybrid system (SHS), perturbation analysis, personalized cancer therapy.
1. INTRODUCTION
Cancer is widely viewed as a “disease of stages” in which
tumors must progress through a series of discrete “states”
in order to ultimately become malignant [Hanahan and
Weinberg (2011)]. This view is particularly suitable to
the development of prostate cancer, which is known to
be a multistep process [Longo et al. (2012)]. For instance,
a patient diagnosed with localized prostate cancer who
has had all the tumor surgically removed is considered
to remain in the state of “localized disease” until he
progresses to a new state. At each state, distinct therapies
can be prescribed, and the time spent by the patient in any
given state is a measure of the efficacy of the corresponding
intervention.
The standard treatment for advanced prostate cancer
patients is hormone therapy in the form of androgen de-
privation [Longo et al. (2012)]. The initial response to an-
drogen deprivation therapy (ADT) is frequently positive,
leading to a significant decrease in tumor size. However,
most patients eventually develop resistance to ADT and
relapse. A generally acceptable mechanism for explaining
such relapse is the existence of an androgen-independent
cancer cell phenotype that is resistant to secondary en-
docrine therapy and whose outgrowth leads to tumor re-
currence [Jackson (2004a)].
Intermittent androgen suppression (IAS) therapy has
been recently proposed as a strategy for delaying or
even preventing time to relapse. The purpose of IAS is
to prevent the exisiting tumor from progressing into an
androgen-independent state. In spite of significant clinical
experience with this approach, defining ideal protocols for
any given patient remains one of the main challenges as-
sociated with effective IAS therapy [Hirata et al. (2010a)].
In fact, recent clinical trials suggest that the success of
IAS ultimately translates into the ability to tailor on and
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off-treatment schemes to individual patients [Bruchovsky
et al. (2006), Bruchovsky et al. (2007)]. The design of op-
timal personalized IAS treatment schemes remains, there-
fore, an unsolved problem.
Recent attempts at addressing this problem have led
to the development of several mathematical models that
explain the evolution of prostate cancer under hormone
therapy. The model from Jackson (2004a) describes the
growth of prostate tumors formed by two subpopulations
of cancer cells, only one of which is sensitive to androgen
deprivation, and successfully reproduces the experimen-
tally observed three phases of tumor evolution; however,
the issue of IAS therapy design was not explicitly ad-
dressed. Ideta et al. (2008) applied a hybrid dynamical
system approach to model prostate tumor evolution under
IAS and then used it to study the effect of different therapy
protocols on tumor growth and time to relapse through
numerical and bifurcation analyses. Several extensions of
the works by Jackson (2004a) and Ideta et al. (2008) have
been proposed and we briefly review some of them. A non-
linear model was developed by Shimada and Aihara (2008)
to account for the competition between different cancer
cell subpopulations, while Tao et al. (2010) proposed a
model based on switched ordinary differential equations.
The problem of individualized prostate cancer treatment
was formulated as an optimal control problem for which
a piecewise affine system model was developed by Suzuki
et al. (2010). Hirata et al. (2010a) modeled the prostate
tumor under IAS as a feedback control system for the pur-
pose of patient classification, while Hirata et al. (2010b)
solved the model from Hirata et al. (2010a) analytically to
derive conditions for patient relapse.
Most of the exisiting models provide insights into the
dynamics of prostate cancer evolution under ADT but do
not address the issue of therapy design. Moreover, previous
work focusing on classifying patients into groups in order
to infer optimal treatment schemes have been based on
more manageable, albeit less accurate, approaches to non-
linear hybrid dynamical systems. In contrast, a nonlinear
hybrid automaton model was recently proposed by Liu
et al. (2015) and δ-reachability analysis was used to iden-
tify patient-specific therapy schemes. Although this model
was shown to be in good agreement with published clinical
data, it did not account for noise and fluctutations that
are inherently associated with cell population dynamics
and monitoring of clinical data. Stochastic effects were
incorporated into a hybrid model of tumor growth under
IAS therapy by Tanaka et al. (2010), but the ensuing anal-
ysis was performed considering a pre-determined therapy
scheme, i.e., no design of personalized therapy was carried
out. This paper is motivated by the need to develop opti-
mal personalized IAS therapy based on stochastic models
of prostate cancer evolution and represents a first attempt
towards this goal using a Stochastic Hybrid Automaton
(SHA) model of cancer progression.
In this paper, we draw upon the deterministic hybrid
automaton model from Liu et al. (2015) to which we
incorporate stochastic effects. We propose a cost metric
in terms of the desired outcome of IAS therapy that is
parameterized by a controllable parameter vector, and for-
mulate the problem of optimal personalized therapy design
as the search for the parameter values which minimize
our cost metric. We use Infinitesimal Perturbation Anal-
ysis (IPA) for hybrid systems [Cassandras et al. (2010)]
to derive gradient estimates of the cost metric with re-
spect to the controllable vector of interest, which can be
subsequently incorporated into a standard gradient-based
optimization algorithm. Our main focus is on establishing
a framework for IPA applications to biologically-inspired
problems which is illustrated here with the case of prostate
cancer therapy design. The advantages of our approach
are twofold: first, we can obtain sensitivity estimates with
respect to the various model parameters from actual data
so as to differentiate critical ones from others that are not.
Moreover, IPA efficiently yields sensitivies with respect to
controllable parameters in a therapy (i.e., control policy),
which is arguably the ultimate goal of personalized therapy
design.
In Section 2 we formulate the problem of personalized
therapy design based on an SHA model of prostate cancer
evolution. Section 3 presents the general framework of IPA
and details the derivation of IPA estimators for therapy
evaluation and optimization. We include final remarks in
Section 4.
2. PROBLEM FORMULATION
2.1 SHA Model of Prostate Cancer Progression
The system we consider comprises a prostate tumor
under IAS therapy, which is modeled as a Stochastic
Hybrid Automaton (SHA). We adopt a standard SHA
definition [Cassandras and Lafortune (2008)]:
Gh = (Q,X,E,U, f, φ, Inv, guard, ρ, q0, x0)
where Q is a set of discrete states; X is a continuous state
space; E is a finite set of events; U is a set of admissible
controls; f is a vector field, f : Q × X × U → X ; φ is a
discrete state transition function, φ : Q×X×E → Q; Inv
is a set defining an invariant condition (when this condition
is violated at some q ∈ Q, a transition must occur); guard
is a set defining a guard condition, guard ⊆ Q × Q × X
(when this condition is satisfied at some q ∈ Q, a transition
is allowed to occur); ρ is a reset function, ρ : Q×Q×X×
E → X ; q0 is an initial discrete state; x0 is an initial
continuous state.
With this framework in place, we define a SHA model
of prostate cancer progression in terms of the following:
1. Discrete state set Q. Hormone therapy for prostate
cancer consists of administering medical agents that cause
androgen suppression in an effort to decrease the popu-
lation of prostate cancer cells and hence the size of the
tumor. A common biomarker used to monitor the efficacy
of such treatment is the serum level of Prostate-Specific
Antigen (PSA), whose value provides an estimate of the
size of the prostate cancer population.
In IAS therapy, medication is suspended when a suffi-
cient reduction in the size of the cancer cell populations
is achieved. Since population sizes are not directly observ-
able, this reduction is estimated in terms of the patient’s
PSA level; hence, the patient goes off therapy once his PSA
reaches a lower threshold value. Similarly, medication is re-
instated once the cancer cell populations have significantly
recovered, which corresponds to when the patient’s PSA
level reaches an upper threshold value. Thus, we define
Q =
{
qON , qOFF
}
, where qON (qOFF , respectively) is
the on-treatment (off-treatment, respectively) operational
mode of the system.
2. State space X . The continuous state space X is de-
fined in terms of the biomarkers commonly monitored dur-
ing IAS therapy, namely the PSA level and the androgen
concentration in the patient’s serum. We assume the co-
existence of two subpopulations of cancer cells within the
tumor: Hormone Sensitive Cells (HSCs) and Castration
Resistant Cells (CRCs). The proliferation of the former is
negatively affected by hormone therapy, while the survival
rate of the latter decreases in androgen-rich environments.
We thus define a state vector x(t) = [x1(t), x2(t), x3(t)]
with xi(t) ∈ R
+, such that x1(t) is the total population
of HSCs, x2(t) is the total population of CRCs, and
x3(t) is the concentration of androgen in the serum. Since
prostate cancer cells secrete high levels of PSA, it is
frequently assumed that the serum PSA concentration can
be modeled as a linear combination of the cancer cell
subpopulations, i.e., c1x1(t) + c2x2(t). Another common
assumption is that both HSCs and CRCs secrete PSA
equivalently, so that c1 = c2 = 1 [Ideta et al. (2008)].
In this work, we adopt these assumptions. We also define
a “clock” state variable zi(t) ∈ R
+, i = 1, 2, where
z1(t) (z2(t), respectively) measures the time spent by the
system in state qON (qOFF , respectively). The clock is
reset to zero once a state transition takes place. Setting
z(t) = [z1(t), z2(t)], the complete state vector is [x(t), z(t)].
3. Event set E. We define the SHA event set as
E = {e1, e2}, where e1 corresponds to the condi-
tion [x1(t) + x2(t) = θ1 from above] and e2 corresponds to
[x1(t) + x2(t) = θ2 from below].
4. Admissible control set U . As described earlier, IAS
therapy consists of cycles of androgen deprivation deliv-
ered intermittently with off-treatment periods. The cycles
of androgen deprivation are suspended when the patient’s
PSA level reaches a lower threshold value, while ther-
apy recommences once the PSA level reaches an upper
threshold value. Hence, an IAS therapy can be viewed as
a controlled process characterized by two parameters: θ =
[θ1, θ2] ∈ Θ, where θ1 ∈
[
θmin1 , θ
max
1
]
is the lower threshold
value of the patient’s PSA level, and θ2 ∈
[
θmin2 , θ
max
2
]
is
the upper threshold value of the patient’s PSA level, with
θmax1 < θ
min
2 . At any time t, the feasible control set for
the IAS therapy controller is U = {0, 1} and the control is
defined as:
u (x(t), z(t)) ≡
{
0 if x1(t) + x2(t) < θ2, q(t) = q
OFF
1 if x1(t) + x2(t) > θ1, q(t) = q
ON
(1)
This is a simple form of hysteresis control to ensure that
hormone therapy will be suspended whenever a patient’s
PSA level drops below a minimum threshold value, and
that therapy will resume whenever a patient’s PSA level
reaches a maximum threshold value.
5. System dynamics. The SHA system dynamics describe
the evolution of continuous state variables over time, as
well as the rules for discrete state transitions. First, the
continuous (time-driven) dynamics capture the prostate
cancer cell population dynamics, which are defined in
terms of their proliferation, apoptosis, and conversion
rates. Existing studies commonly use Michaelis-Menten-
like functions to model the rates of proliferation and
apoptosis [Ideta et al. (2008), Jackson (2004a), Jackson
(2004b)]. Recently Liu et al. (2015) obtained greater con-
sistency between clinical data and simulated population
dynamics by modeling these rates using sigmoid functions.
In what follows, we incorporate stochastic effects into the
deterministic model from Liu et al. (2015) and obtain:
x˙1(t) = α1
[
1 + e−(x3(t)−k1)k2
]−1
· x1(t)
−β1
[
1 + e−(x3(t)−k3)k4
]−1
· x1(t)
−
[
m1
(
1−
x3(t)
x3,0
)
+ λ1
]
· x1(t)
+µ1 + ζ1(t)
(2)
x˙2(t) =
[
α2
(
1− d
x3(t)
x3,0
)
− β2
]
x2(t)
+m1
(
1−
x3(t)
x3,0
)
x1(t) + ζ2(t)
(3)
x˙3(t) =


−
x3(t)
σ
+ µ3 + ζ3(t)
if x1(t) + x2(t) > θ1
and q(t) = qON
x3,0 − x3(t)
σ
+ µ3 + ζ3(t)
if x1(t) + x2(t) < θ2
and q(t) = qOFF
(4)
z˙1(t) =
{
1 if q(t) = qON
0 otherwise
(5)
z1(t
+) = 0
if x1(t) + x2(t) = θ1
and q(t) = qON
z˙2(t) =
{
1 if q(t) = qOFF
0 otherwise
(6)
z2(t
+) = 0
if x1(t) + x2(t) = θ2
and q(t) = qOFF
where α1 and α2 are the HSC proliferation constant and
CRC proliferation constant, respectively; β1 and β2 are
the HSC apoptosis constant and CRC apoptosis con-
stant, respectively; k1 through k4 are HSC proliferation
and apoptosis exponential constants; m1 is the HSC to
CRC conversion constant; x3,0 corresponds to the patient-
specific androgen constant; σ is the androgen degradation
constant; λ1 is the HSC basal degradation rate; µ1 and
µ3 are the HSC basal production rate and androgen basal
production rate, respectively. Finally, {ζi(t)}, i = 1, 2, 3,
are stochastic processes which we allow to have arbitrary
characteristics and only assume them to be piecewise con-
tinuous w.p. 1.
Observe that (2) and (3) seem to be independent of the
discrete state (mode) q(t); however, their dependence on
x3(t), whose dynamics are affected by mode transitions,
implies that x1(t), x2(t) also change due to such transi-
tions. To make this behavior explicit, we can solve (4)
for x3(t) and substitute this solution into (2) and (3), as
detailed next.
Consider a sample path of the system over [0, T ] and
denote the time of occurrence of the kth event (of any
type) by τk(θ). Since our complete system state vector is
[x(t), z(t)], we shall denote the state dynamics over any
interevent interval [τk(θ), τk+1(θ)) as follows:
x˙n(t) = f
x
n,k(t), z˙i(t) = f
z
i,k(t), n = 1, . . . , 3, i = 1, 2
Although we include θ as an argument in the expressions
above to stress the dependence on the controllable param-
eter, we will subsequently drop this for ease of notation as
long as no confusion arises.
We start our analysis by assuming q(t) = qON for t ∈
[τk, τk+1). It is clear from (4) that x˙3(t) = −
x3(t)
σ + µ3 +
ζ3(t), which implies that, for t ∈ [τk, τk+1),
x3(t) = x3(τ
+
k )e
−(t−τk)/σ
+e−t/σ ·
∫ t
τk
eε/σ [µ3 + ζ3(ε)] dε
For notational simplicity, let
ζ˜3(t) =
∫ t
τk
e−(t−ε)/σζ3(ε)dε (7)
and define, for t ∈ [τk, τk+1),
hON
(
t, ζ˜3(t)
)
≡ x3(τ
+
k )e
−(t−τk)/σ
+µ3σ[1 − e
−(t−τk)/σ] + ζ˜3(t)
(8)
Now let q(t) = qOFF for t ∈ [τk, τk+1), so that (4) implies
that, for t ∈ [τk, τk+1),
x3(t) = x3(τ
+
k )e
−(t−τk)/σ
+(µ3σ + x3,0)[1− e
−(t−τk)/σ] + ζ˜3(t)
Similarly as above, we define, for t ∈ [τk, τk+1),
hOFF
(
t, ζ˜3(t)
)
≡ x3(τ
+
k )e
−(t−τk)/σ
+(µ3σ + x3,0)[1− e
−(t−τk)/σ] + ζ˜3(t)
(9)
It is thus clear that
x3(t) =


hON
(
t, ζ˜3(t)
)
if q(t) = qON
hOFF
(
t, ζ˜3(t)
)
if q(t) = qOFF
Although we include ζ˜3(t) as an argument in (8)-(9) to
stress the dependence on the stochastic process, we will
subsequently drop this for ease of notation as long as no
confusion arises. It is now clear that, by using (8)-(9) in
(2)-(3), we may rewrite the state variable dynamics as
x˙1(t) =


{
α1
[
1 + φONα (t)
]−1
− β1
[
1 + φONβ (t)
]−1
+m1
(
hON (t)
x3,0
)
− (m1 + λ1)
}
· x1(t)
+µ1 + ζ1(t) if q(t) = q
ON{
α1
[
1 + φOFFα (t)
]−1
− β1
[
1 + φOFFβ (t)
]−1
+m1
(
hOFF (t)
x3,0
)
− (m1 + λ1)
}
· x1(t)
+µ1 + ζ1(t) if q(t) = q
OFF
(10)
and
x˙2(t) =


[
α2
(
1− d
hON (t)
x3,0
)
− β2
]
x2(t)
+m1
(
1−
hON (t)
x3,0
)
x1(t) + ζ2(t)
if q(t) = qON[
α2
(
1− d
hOFF (t)
x3,0
)
− β2
]
x2(t)
+m1
(
1−
hOFF (t)
x3,0
)
x1(t) + ζ2(t)
if q(t) = qOFF
(11)
with
φONα (t) = e
−(hON (t)−k1)k2
φONβ (t) = e
−(hON (t)−k3)k4
φOFFα (t) = e
−(hOFF (t)−k1)k2
φOFFβ (t) = e
−(hOFF (t)−k3)k4
The discrete (event-driven) dynamics are dictated by
the occurrence of events that cause state transitions. Based
on the event set E = {e1, e2} we have defined, the
occurrence of e1 results in a transition from q
ON to qOFF
and the occurrence of e2 results in a transition from q
OFF
to qON .
2.2 IAS Therapy Evaluation and Optimization
The effect of an IAS therapy u (θ, t) depends on the
controllable parameter vector θ, as in (1), and can be
quantified in terms of performance metrics of the form
J [u(θ, t)]. Evaluating J [u(θ, t)] over all possible values
of θ is clearly infeasible. However, there exist very effi-
cient ways to accomplish this goal for stochastic hybrid
systems. In particular, Perturbation Analysis (PA) is a
methodology to efficiently estimate the sensitivity of the
performance with respect to θ, i.e., when θ is a real-valued
scalar, the derivative dJ/dθ. This is accomplished by ex-
tracting data from a sample path (simulated or actual) of
the observed system based on which an unbiased estimate
of dJ/dθ can indeed be obtained. The attractive feature
of PA is that the resulting estimates are extracted from
a single sample path in a non-intrusive manner and the
computational cost of doing so is, in most cases of interest,
minimal [Cassandras and Lafortune (2008)]. This is in
contrast to the the conventional finite difference estimate
of dJ/dθ obtained through [J(θ+∆)−J(θ)]/∆. Thus, for
a vector θ of dimension N , estimating the gradient ∇J (θ)
requires a single sample path (with some overhead) instead
of N +1 sample paths. The simplest family of PA estima-
tors is Infinitesimal Perturbation Analysis (IPA). For the
SHA model we consider here, IPA has been recently shown
to provide unbiased gradient estimates [Cassandras et al.
(2010)] for virtually arbitrary stochastic hybrid systems.
Our goal, therefore, is to adapt IPA estimators of the
form dJ [u(θ, t)]/dθ for different therapies u(θ, t), thus es-
timating their effects, and to ultimately show that optimal
therapy schemes can be designed by solving problems of
the form minθ∈Θ J [u(θ, t)].
We define a sample function in terms of complementary
measures of therapy success. In particular, we take the
most adequate treatment schemes to be those that (i)
ensure PSA levels are kept as low as possible; (ii) reduce
the frequency of on and off-treatment cycles. There is an
obvious trade-off between (i) and the cost associated with
(ii), which is related to the duration of the therapy and
could potentially include fixed set up costs incurred when
therapy is reinstated. For simplicity, we disconsider fixed
set up costs and take (ii) to be linearly proportional to
the length of the on-treatment cycles. We thus associate
weights Wi, i = 1, 2, with (i) and (ii), respectively, and
define our sample function as the sum of the average PSA
level and the average duration of an on-treatment cycle
over a fixed time interval [0, T ]. We also normalize our
sample function to ensure that the trade-off between (i)
and (ii) is captured appropriately: we divide (i) by the
value of the patient’s PSA level at the start of the first on-
treatment cycle (PSAinit), and note that (ii) is naturally
normalized by T . Recall that the total population size of
prostate cancer cells is assumed to reflect the serum PSA
concentration, and that we have defined clock variables
which measure the time elapsed in each of the treatment
modes, so that our sample function can be written as
L (θ, x(0), z(0), T ) =
1
T
[
W1
∫ T
0
[
x1(θ, t) + x2(θ, t)
PSAinit
]
dt
+ W2
∫ T
0
z1(t)dt
]
(12)
where x(0) and z(0) are given initial conditions. We can
then define the overall performance metric as
J (θ, x(0), z(0), T ) = E [L (θ, x(0), z(0), T )] (13)
Hence, the problem of determining the optimal IAS
therapy can be formulated as
min
θ∈Θ
E [L (θ, x(0), z(0), T )] (14)
3. INFINITESIMAL PERTURBATION ANALYSIS
Consider a sample path generated by the SHA over [0, T ]
and recall that we have defined τk(θ) to be the time of
occurrence of the kth event (of any type), where θ is a
controllable parameter vector of interest. We denote the
state and event time derivatives with respect to parameter
θ as x′(θ, t) ≡ dx(θ,t)dθ and τ
′
k(θ) ≡
dτk(θ)
dθ , respectively, for
k = 1, . . . , N . As mentioned earlier, the dynamics of x(θ, t)
are fixed over any interevent interval [τk(θ), τk+1(θ)] and
we write x˙(t) = fk (θ, x, t) to represent the state dynamics
over this interval. Although we include θ as an argument
in the expressions above to stress the dependence on the
controllable parameter, we will subsequently drop this
for ease of notation as long as no confusion arises. It is
shown in Cassandras et al. (2010) that the state derivative
satisfies
d
dt
x′(t) =
dfk(t)
dx
x′(t) +
dfk(t)
dθ
(15)
with the following boundary condition:
x′(τ+k ) = x
′(τ−k ) +
[
fk−1(τ
−
k )− fk(τ
+
k )
]
· τ ′k (16)
We note that (16) is valid when x(θ, t) is continuous in t
at t = τk. If this is not the case and the value of x(τ
+
k ) is
determined by the reset function ρ (q, q′, x, e), then
x′(τ+k ) =
dρ (q, q′, x, e)
dθ
(17)
Knowledge of τ ′k is, therefore, needed in order to evaluate
(16). Following the framework in Cassandras et al. (2010),
there are three types of events for a general stochas-
tic hybrid system: (i) Exogenous Events. These events
cause a discrete state transition independent of θ and
satisfy τ ′k = 0. (ii) Endogenous Events. Such an event
occurs at time τk if there exists a continuously differ-
entiable function gk : R
n × Θ → R such that τk =
min {t > τk−1 : gk (x(θ, t), θ) = 0}, where the function gk
usually corresponds to a guard condition in a hybrid
automaton. Taking derivatives with respect to θ, it is
straighforward to obtain
τ ′k = −
[
dgk
dx
· fk−1(τ
−
k )
]−1
·
(
dgk
dθ
+
dgk
dx
· x′(τ−k )
)
(18)
as long as dgkdx ·fk−1(τ
−
k ) 6= 0. (iii) Induced Events. Such an
event occurs at time τk if it is triggered by the occurrence
of another event at time τm ≤ τk (details can be found in
Cassandras et al. (2010)).
Returning to our problem of personalized prostate can-
cer therapy design, we define the derivatives of the states
xn(θ, t) and zj(θ, t) and event times τk(θ) with respect to
θi, i, j = 1, 2, n = 1, . . . , 3, as follows:
x′n,i(t) ≡
∂xn(θ, t)
∂θi
, z′j,i(t) ≡
∂zj(θ, t)
∂θi
, τ ′k,i ≡
∂τk(θ)
∂θi
(19)
Our goal is to obtain an estimate of ∇J(θ) by evaluating
the sample gradient ∇L(θ), which is computed using data
extracted from a sample path of the system (e.g., by
simulating a sample path of our SHA model using clinical
data). We will assume that the derivatives dL/dθi exist
w.p. 1 for all θi ∈ R
+. It is also easy to verify that L (θ) is
Lipschitz continuous for θi ∈ R
+. We will further assume
that no two events can occur at the same time w.p.1. Under
these conditions, it has been shown in Cassandras et al.
(2010) that dL/dθi is an unbiased estimator of dJ/dθi,
i = 1, 2.
In what follows, we derive the IPA state and event time
derivatives for the events indentified in our SHA model of
prostate cancer progression.
3.1 State and Event Time Derivatives
We begin by analyzing the state evolution considering
each of the states (qON and qOFF ) and events (e1 and e2)
defined for our SHA model.
1. q(t) = qON for t ∈ [τk, τk+1). Using (15) for x1(t), we
have, for i = 1, 2,
d
dt
x′1,i(t) =
∂fx1k (t)
∂x1
x′1(t) +
∂fx1k (t)
∂x2
x′2(t) +
∂fx1k (t)
∂x3
x′3(t)
+
∂fx1k (t)
∂z1
z′1(t) +
∂fx1k (t)
∂z2
z′2(t) +
∂fx1k (t)
∂θi
From (10), we have
∂f
x1
k
(t)
∂xn
=
∂f
x1
k
(t)
∂zi
=
∂f
x1
k
(t)
∂θi
= 0,
n = 2, 3, i = 1, 2, and
∂fx1k (t)
∂x1
= α1
[
1 + φONα (t)
]−1
− β1
[
1 + φONβ (t)
]−1
−m1
(
1−
hON (t)
x3,0
)
− λ1
(20)
Combining the last two equations and solving for x′1,i(t),
we obtain
x′1,i(t) = x
′
1,i(τ
+
k )e
A(t), t ∈ [τk, τk+1) (21)
and, in particular,
x′1,i(τ
−
k+1) = x
′
1,i(τ
+
k )e
A(τk) (22)
with
A (τk) ≡
∫ τk+1
τk
[
α1
1 + φONα (t)
−
β1
1 + φONβ (t)
]
dt
−
∫ τk+1
τk
m1
x3,0
hON (t) dt− (m1 + λ1) (τk+1 − τk)
Similarly for x2(t), we have from (11) that
∂f
x2
k
(t)
∂x3
=
∂f
x2
k
(t)
∂zi
=
∂f
x2
k
(t)
∂θi
= 0, i = 1, 2, and
∂fx2k (t)
∂x1
= m1
(
1−
hON (t)
x3,0
)
∂fx2k (t)
∂x2
= α2
(
1− d
hON (t)
x3,0
)
− β2
(23)
Combining the last two equations and solving for x′2,i(t)
yields, for t ∈ [τk, τk+1),
x′2,i(t) = x
′
2,i(τ
+
k )e
B1(t) +B2
(
t, x′1,i(τ
+
k ), A (t)
)
(24)
and, in particular,
x′2,i(τ
−
k+1) = x
′
2,i(τ
+
k )e
B1(τk) +B2
(
τk, x
′
1,i(τ
+
k ), A (τk)
)
(25)
with
B1 (τk) ≡
∫ τk+1
τk
[
α2
(
1− d
hON (t)
x3,0
)
− β2
]
dt
B2 (·) ≡ e
B1(τk)
∫ τk+1
τk
G1 (t, τk) e
−B1(τk)dt
where G1 (t, τk) = m1
(
1− h
ON (t)
x3,0
)
x′1,i(τ
+
k )e
A(t), t ∈
[τk, τk+1).
In the case of x3(t), it is clear from (4) that
∂f
x3
k
(t)
∂xi
=
∂f
x3
k
(t)
∂zi
=
∂f
x3
k
(t)
∂θi
= 0, i = 1, 2, and
∂f
x3
k
(t)
∂x3
= − 1σ .
Substituting in (15) and solving for x′3,i(t), for i = 1, 2,
yields x′3,i(t) = x
′
3,i(τ
+
k )e
−(t−τk)/σ, t ∈ [τk, τk+1), and, in
particular,
x′3,i(τ
−
k+1) = x
′
3,i(τ
+
k )e
−(t−τk)/σ (26)
Finally, in the case of the ”clock” state variable zi(θ, t),
i = 1, 2, based on (5) and (6), we have
∂f
zi
k
(t)
∂xn
=
∂f
zi
k
(t)
∂zi
=
∂f
zi
k
(t)
∂θi
= 0, n = 1, . . . , 3, i = 1, 2, so that ddtz
′(t) = 0
for t ∈ [τk, τk+1). This means that the value of the state
derivative of the ”clock” variable remains unaltered while
q(t) = qON , i.e., z′i(t) = z
′
i(τ
+
k ), t ∈ [τk, τk+1).
2. q(t) = qOFF for t ∈ [τk, τk+1). Starting with x1(t), a
similar reasoning as above applies, but now we have
∂fx1k (t)
∂x1
= α1
[
1 + φOFFα (t)
]−1
− β1
[
1 + φOFFβ (t)
]−1
−m1
(
1−
hOFF (t)
x3,0
)
− λ1
As a result, (15) implies that, for i = 1, 2,
x′1,i(t) = x
′
1,i(τ
+
k )e
C(t), t ∈ [τk, τk+1) (27)
and, in particular,
x′1,i(τ
−
k+1) = x
′
1,i(τ
+
k )e
C(τk) (28)
with
C (τk) ≡
∫ τk+1
τk
[
α1
1 + φOFFα (t)
−
β1
1 + φOFFβ (t)
]
dt
−
∫ τk+1
τk
m1
x3,0
hOFF (t) dt− (m1 + λ1) (τk+1 − τk)
Similarly for x2(t), we have
∂fx2k (t)
∂x1
= m1
(
1−
hOFF (t)
x3,0
)
∂fx2k (t)
∂x2
= α2
(
1− d
hOFF (t)
x3,0
)
− β2
It is thus straightforward to verify that (15) yields, for
t ∈ [τk, τk+1),
x′2,i(t) = x
′
2,i(τ
+
k )e
D1(t) +D2
(
t, x′1,i(τ
+
k ), C (t)
)
(29)
and, in particular,
x′2,i(τ
−
k+1) = x
′
2,i(τ
+
k )e
D1(τk) +D2
(
τk, x
′
1,i(τ
+
k ), C (τk)
)
(30)
with
D1 (τk) ≡
∫ τk+1
τk
[
α2
(
1− d
hOFF (t)
x3,0
)
− β2
]
dt
D2 (·) ≡ e
D1(τk)
∫ τk+1
τk
G2 (t, τk) e
−D1(τk)dt
where G2 (t, τk) = m1
(
1− h
OFF (t)
x3,0
)
x′1,i(τ
+
k )e
C(t), t ∈
[τk, τk+1).
In the case of x3(t), we will have
∂f
x3
k
(t)
∂xi
=
∂f
x3
k
(t)
∂zi
=
∂f
x3
k
(t)
∂θi
= 0, i = 1, 2, and
∂f
x3
k
(t)
∂x3
= − 1σ , so that (15)
implies x′3,i(t) = x
′
3,i(τ
+
k )e
−(t−τk)/σ, t ∈ [τk, τk+1), and,
in particular,
x′3,i(τ
−
k+1) = x
′
3,i(τ
+
k )e
−(t−τk)/σ (31)
Finally, in the case of the ”clock” state variable zi(θ, t),
i = 1, 2, based on (5) and (6), we have
∂f
zi
k
(t)
∂xn
=
∂f
zi
k
(t)
∂zi
=
∂f
zi
k
(t)
∂θi
= 0, n = 1, . . . , 3, i = 1, 2, so that ddtz
′(t) = 0
for t ∈ [τk, τk+1). This means that the value of the state
derivative of the ”clock” variable remains unaltered while
q(t) = qOFF , i.e., z′i(t) = z
′
i(τ
+
k ), t ∈ [τk, τk+1).
3. A state transition from qON to qOFF takes place at
time τk. This necessarily implies that event e1 occurred at
time τk. From (16) we have, for i = 1, 2,
x′1,i(τ
+
k ) = x
′
1,i(τ
−
k ) +
[
fx1k (τ
−
k )− f
x1
k+1(τ
+
k )
]
· τ ′k,i (32)
Observe that, from (10), fx1k (τ
−
k ) and f
x1
k+1(τ
+
k ) ulti-
mately depend on hON
(
τ−k
)
and hOFF
(
τ+k
)
, respectively.
Also, a transition from qON to qOFF at time τk implies
that q(t) = qON , t ∈ [τk−1, τk) and q(t) = q
OFF , t ∈
[τk, τk+1). Hence, evaluating h
ON
(
τ−k
)
from (8) over the
appropriate time interval results in
hON
(
τ−k
)
= x3(τ
+
k−1)e
−(τk−τk−1)/σ
+µ3σ[1 − e
−(τk−τk−1)/σ] + ζ˜3(τk)
and it follows directly from (9) that hOFF
(
τ+k
)
= x3(τ
+
k ).
Furthermore, by continuity of xn(t) (due to conservation
of mass), xn(τ
+
k ) = xn(τ
−
k ), n = 1, 2, 3. Also, since we have
assumed that {ζi(t)}, i = 1, 2, 3, is piecewise continuous
w.p.1 and that no two events can occur at the same time
w.p.1, ζi(τ
−
k ) = ζi(τ
+
k ), i = 1, 2, 3. Hence, by evaluating
∆1f (τk) ≡ f
x1
k (τ
−
k )− f
x1
k+1(τ
+
k ) we obtain
∆1f (τk, ζ3 (τk)) =
{
α1
[
1 + φONα (τ
−
k )
]−1
− α1
[
1 + φOFFα (τ
+
k )
]−1
− β1
[
1 + φONβ (τ
−
k )
]−1
+ β1
[
1 + φOFFβ (τ
+
k )
]−1
+
m1
x3,0
[
hON
(
τ−k
)
− x3(τk)
]}
· x1(τk)
(33)
Finally, the term τ ′k,i, which corresponds to the event
time derivative with respect to θi at event time τk, is
determined using (18), as will be detailed in Lemma 1
later.
A similar analysis applies to x2(t), so that, for i = 1, 2,
x′2,i(τ
+
k ) = x
′
2,i(τ
−
k ) +
[
fx2k (τ
−
k )− f
x2
k+1(τ
+
k )
]
· τ ′k,i (34)
where τ ′k,i will be derived in Lemma 1, and f
x2
k (τ
−
k ) and
fx2k+1(τ
+
k ) ultimately depend on h
ON
(
τ−k
)
and hOFF
(
τ+k
)
,
respectively. Hence, evaluating ∆2f (τk) ≡ f
x2
k (τ
−
k ) −
fx2k+1(τ
+
k ) from (11) yields
∆2f (τk, ζ3 (τk)) =
α2d
x3,0
[
x3(τk)− h
ON
(
τ−k
)]
· x2(τk)
−
m1
x3,0
[
hON
(
τ−k
)
− x3(τk)
]
· x1(τk)
(35)
Finally, for x3(t), (16) can be easily seen to yield, for
i = 1, 2,
x′3,i(τ
+
k ) = x
′
3,i(τ
−
k )−
x3,0
σ
· τ ′k,i
In the case of the ”clock” state variable, z1(t) is discon-
tinuous in t at t = τk, while z2(t) is continuous. Applying
(17) to the reset function defined in (5) yields z′1,i(τ
+
k ) = 0,
i = 1, 2, i.e., the value of z′1,i(t) is reset to zero whenever
event e1 takes place. Based on (16) and (6), it is simple to
verify that, for i = 1, 2,
z′2,i(τ
+
k ) = z
′
2,i(τ
−
k )− τ
′
k,i
4. A state transition from qOFF to qON takes place at
time τk. This necessarily implies that event e2 occurred
at time τk. The same reasoning as above applies and from
(16) we have, for i = 1, 2,
x′1,i(τ
+
k ) = x
′
1,i(τ
−
k ) +
[
f1k (τ
−
k )− f
1
k+1(τ
+
k )
]
· τ ′k,i (36)
where f1k (τ
−
k )− f
1
k+1(τ
+
k ) can be evaluated from (10) and
ultimately depends on hOFF
(
τ−k
)
and hON
(
τ+k
)
. Recall
that a transition from qOFF to qON at time τk implies
that q(t) = qOFF , t ∈ [τk−1, τk) and q(t) = q
ON , t ∈
[τk, τk+1). Hence, evaluating h
OFF
(
τ−k
)
from (9) over the
appropriate time interval results in
hOFF
(
τ−k
)
= x3(τ
+
k−1)e
−(τk−τk−1)/σ
+(µ3σ + x3,0)[1 − e
−(τk−τk−1)/σ] + ζ˜3(τk)
and it follows directly from (8) that hON
(
τ+k
)
= x3(τ
+
k ).
As in the previous case, continuity due to conservation
of mass applies, so that evaluating ∆1f (τk) ≡ f
1
k (τ
−
k ) −
f1k+1(τ
+
k ) yields
∆1f (τk, ζ3 (τk)) =
{
α1
[
1 + φOFFα (τ
−
k )
]−1
− α1
[
1 + φONα (τ
+
k )
]−1
− β1
[
1 + φOFFβ (τ
−
k )
]−1
+ β1
[
1 + φONβ (τ
+
k )
]−1
+
m1
x3,0
[
hOFF
(
τ−k
)
− x3(τk)
]}
· x1(τk)
(37)
The term τ ′k,i corresponds to the event time derivative
with respect to θi at event time τk and its derivation will
be detailed in Lemma 1.
Similarly for x2(t), we have, for i = 1, 2,
x′2,i(τ
+
k ) = x
′
2,i(τ
−
k ) +
[
f2k (τ
−
k )− f
2
k+1(τ
+
k )
]
· τ ′k,i (38)
where τ ′k,i will be derived in Lemma 1. Evaluating
∆2f (τk) ≡ f
2
k (τ
−
k ) − f
2
k+1(τ
+
k ) from (11), and making the
appropriate simplifications due to continuity, we obtain
∆2f (τk, ζ3 (τk)) =
α2d
x3,0
[
x3(τk)− h
OFF
(
τ−k
)]
· x2(τk)
−
m1
x3,0
[
hOFF
(
τ−k
)
− x3(τk)
]
· x1(τk)
(39)
Finally, for x3(t), (16) can be easily seen to yield
x′3,i(τ
+
k ) = x
′
3,i(τ
−
k ) +
x3,0
σ · τ
′
k,i, i = 1, 2.
In the case of the ”clock” state variable, z1(t) is contin-
uous in t at t = τk, while z2(t) is discontinuous. Based on
(16) and (5), it is simple to verify that, for i = 1, 2,
z′1,i(τ
+
k ) = z
′
1,i(τ
−
k )− τ
′
k,i
Applying (17) to the reset function defined in (6) yields
z′2,i(τ
+
k ) = 0, i = 1, 2, i.e., the value of z
′
2,i(t) is reset to
zero whenever event e2 takes place.
Note that, since z′j,i(t) = z
′
j,i(τ
+
k ), t ∈ [τk, τk+1), we
will have that z′j,i(τ
−
k ) = z
′
j,i(τ
+
k−1), j, i = 1, 2. Moreover,
the sample path of our SHA consists of a sequence of
alternating e1 and e2 events, which implies that z
′
1,i(τ
−
k ) =
0 if event e1 occurred at τk−1, while z
′
2,i(τ
−
k ) = 0 if event
e2 occurred at τk−1. As a result,
z′1,i(τ
+
k ) =
{
−τ ′k,i if event e2 occurs at τk
0 otherwise
(40)
and
z′2,i(τ
+
k ) =
{
−τ ′k,i if event e1 occurs at τk
0 otherwise
(41)
We now proceed with a general result which applies to
all events defined for our SHA model. Let us denote the
time of occurrence of the jth state transition by τj , and
define its derivative with respect to the control parameters
as τ ′j,i ≡
∂τj
∂θi
, i = 1, 2. We also define fxnj (τj) ≡ x˙n(τj),
n = 1, . . . , 3 and note that at each state transition at time
τj an event ep, p = 1, 2, will take place.
Lemma 1. When an event ep, p = 1, 2, occurs, the deriva-
tive τ ′j,i, i = 1, 2, of state transition times τj , j = 1, 2, . . .
with respect to the control parameters θi, i = 1, 2, satisfies:
τ ′j,i =
1 [p = i]− x′1(τ
−
j )− x
′
2(τ
−
j )
fx1j−1(τ
−
j ) + f
x2
j−1(τ
−
j )
(42)
where 1 [p = i] is the usual indicator function.
Proof.We begin with an occurrence of event e1 which
causes a transition from state qON to state qOFF at time
τj . This implies that gj(x, θ) = x1 + x2 − θ1 = 0. As a
result, ∂gk∂x1 =
∂gk
∂x2
= 1, ∂gk∂x3 =
∂gk
∂zi
= ∂gk∂θ2 = 0, i = 1, 2, and
∂gk
∂θ1
= −1, and it is simple to verify that (42) follows from
(18).
Next, consider event e2 at time τj , leading to a transition
from state qOFF to state qON . In this case, gj(x, θ) = x1+
x2 − θ2 = 0, so that
∂gk
∂x1
= ∂gk∂x2 = 1,
∂gk
∂x3
= ∂gk∂zi =
∂gk
∂θ1
= 0,
i = 1, 2, and ∂gk∂θ2 = −1. Substituting into (18) once again
yields (42).
We note that the numerator in (42) is determined using
(22) and (25) if q(τ−j ) = q
ON , or (28) and (30) if q(τ−j ) =
qOFF . Moreover, the denominator in (42) is computed
using (10)-(11) and it is simple to verify that, if event
e1 takes place at time τj ,
fx1j−1(τ
−
j ) + f
x2
j−1(τ
−
j ) = α1
[
1 + φONα (τ
−
j )
]−1
· x1(τj)
−
{
β1
[
1 + φONβ (τ
−
j )
]−1
+ λ1
}
· x1(τj) + µ1
+
[
α2
(
1− d
hON
(
τ−j
)
x3,0
)
− β2
]
· x2(τj)
+ ζ1(τj) + ζ2(τj)
and, if event e2 takes place at time τj ,
fx1j−1(τ
−
j ) + f
x2
j−1(τ
−
j ) = α1
[
1 + φOFFα (τ
−
j )
]−1
· x1(τj)
−
{
β1
[
1 + φOFFβ (τ
−
j )
]−1
+ λ1
}
· x1(τj) + µ1
+
[
α2
(
1− d
hOFF
(
τ−j
)
x3,0
)
− β2
]
· x2(τj)
+ ζ1(τj) + ζ2(τj)
This completes the derivation of all state and event time
derivatives required to apply IPA to the hybrid automaton
model of prostate cancer. In what follows, we shall derive
the cost derivatives corresponding to the performance
metric defined in (12).
3.2 Cost Derivative
Let us denote the total number of on and off-treatment
periods (complete or incomplete) in [0, T ] by KT . Also let
ξk denote the start of the k
th period and ηk denote the end
of the kth period (of either type). Finally, let MT = ⌊
KT
2 ⌋
be the total number of complete on-treatment periods,
and ∆ONm denote the duration of the m
th complete on-
treatment period, where clearly
∆ONm ≡ ηm − ξm
Theorem 1. The derivative of the sample function L(θ)
with respect to the control parameters satisfies:
dL(θ)
dθi
=
W1
T
KT∑
k=1
∫ ηk
ξk
[
x′1,i(θ, t) + x
′
2,i(θ, t)
PSAinit
]
dt
+
W2
T
MT∑
m=1
∆ONm ·
(
η′m,i − ξ
′
m,i
)
−
W2
T
1
[
⌊
KT
2
⌋ 6=
KT
2
]
· ξ′MT+1,i · (T − ξMT+1)
(43)
Proof.We assume, without loss of generality, that the
start of our sample path will coincide with the start of
the first on-treatment period. Note also that we choose
to end our sample path at time T , and that this choice
is independent of θi, i = 1, 2. Consequently, we will have
[0, T ] ≡ [ξ1, ηKT ], which implies that
∂ξ1
∂θi
=
∂ηKT
∂θi
= 0,
i = 1, 2. Recall, from the definition of an intermittent
hormone therapy scheme, that the sample path of our SHA
will consist of alternating on and off-treatment periods.
Since z1(t) = 0 when q(t) = q
OFF , we can rewrite (12) as
L (θ, x(0), z(0), T ) =
W1
T
KT∑
k=1
∫ ηk
ξk
[
x1(θ, t) + x2(θ, t)
PSAinit
]
dt
+
W2
T
[
MT∑
m=1
∫ ηk
ξk
z1(t)dt+
∫ T
ξMT +1
z1(t)dt
]
(44)
Note that our sample path can either (a) end with
an incomplete on-treatment period, or (b) end with an
incomplete off-treatment period. In (44), we assume that
(a) holds, since (b) is a special case of (a) for which∫ T
0
z1(t)dt =
MT∑
m=1
∫ ηm
ξm
z1(t)dt. Observe that the end of
an on-treatment period is coupled with the start of the
subsequent off-treatment period, i.e., xi (ηk) = xi (ξk+1),
i = 1, 2, k = 1, . . . ,KT −1. Using this notation and taking
the derivative of (44) yields
dL(θ)
dθi
=
W1
T · PSAinit
KT−1∑
k=1
∫ ξk+1
ξk
[
x′1,i(θ, t) + x
′
2,i(θ, t)
]
dt
+
W1
T · PSAinit
KT−1∑
k=1
[x1 (ξk+1) + x2 (ξk+1)]
∂ξk+1
∂θi
−
W1
T · PSAinit
KT−1∑
k=1
[x1 (ξk) + x2 (ξk)]
∂ξk
∂θi
+
W1
T · PSAinit
∫ T
ξKT
[
x′1,i(θ, t) + x
′
2,i(θ, t)
]
dt
+
W1
T · PSAinit
[x1(T ) + x2(T )]
∂T
∂θi
−
W1
T · PSAinit
[x1(ξKT ) + x2(ξKT )]
∂ξKT
∂θi
+
W2
T
MT∑
m=1
[∫ ηm
ξm
z′1,i(t)dt+ z1(η
−
m)
∂ηm
∂θi
− z1(ξ
+
m)
∂ξm
∂θi
]
+
W2
T
∫ T
ξMT +1
z′1,i(t)dt + z1(T
−)
∂T
∂θi
− z1(ξ
+
MT+1
)
∂ξM+1
∂θi
(45)
Observe that the first two summation terms in (45)
simplify to
KT−1∑
k=1
[x1 (ξk+1) + x2 (ξk+1)]
∂ξk+1
∂θi
−
KT−1∑
k=1
[x1 (ξk) + x2 (ξk)]
∂ξk
∂θi
= [x1(ξ1) + x2(ξ1)]
∂ξ1
∂θi
+ [x1(ξKT ) + x2(ξKT )]
∂ξKT
∂θi
(46)
Further note that the sixth term in (45) cancels out with
the second term on the right hand side of (46). Moreover,
it is clear from (5) that z1(ξ
+
MT+1
) = z1(ξ
+
m) = 0 and
z1(η
−
m) = ηm−ξm,m = 1, . . . ,MT . Since z
′
j,i(t) = z
′
j,i(τ
+
k ),
j, i = 1, 2, over any interevent interval [τk, τk+1), and
recalling that ∂T∂θi =
∂ξ1
∂θi
= 0, the last two terms in (45)
simplify to
W2
T
MT∑
m=1
[
z′1,i(ξ
+
m) (ηm − ξm) + (ηm − ξm)
∂ηm
∂θi
]
+
W2
T
z′1,i(ξ
+
MT+1
) (T − ξMT+1)
Recall that ξm is the start of the mth on-treatment period,
which necessarily corresponds to the m − 1th occurrence
of event e2. Hence, it follows from (40) that z
′
1,i(ξ
+
m) =
−ξ
′
m,i, m = 1, . . . ,MT+1. As a result, (45) can be further
simplified to
dL(θ)
dθi
=
W1
T · PSAinit
KT−1∑
k=1
∫ ξk+1
ξk
[
x′1,i(θ, t) + x
′
2,i(θ, t)
]
dt
+
W1
T · PSAinit
∫ T
ξKT
[
x′1,i(θ, t) + x
′
2,i(θ, t)
]
dt
+
W2
T
[
MT∑
m=1
− ξ
′
m,i (ηm − ξm) + (ηm − ξm) η
′
m,i
]
−
W2
T
ξ
′
MT+1 (T − ξMT+1)
(47)
The result in (47) is obtained under the assumption that
our sample path ends with an incomplete on-treatment
period. This condition is satisfied when ⌊KT2 ⌋ 6=
KT
2 . If
this is not the case, i.e., if the sample path ends with an
incomplete off-treatment period and ⌊KT2 ⌋ =
KT
2 , the last
term in (47) can be disregarded. It is then straightforward
to verify that (47) can be rewritten as (43).
Observe that evaluating (43) requires knowledge of
x′1,i(θ, t) and x
′
2,i(θ, t) over all on and off-treatment pe-
riods. Over on-treatment periods, this can be determined
using (21) and (24), which ultimately depend on (8), so
that it is necessary to evaluate the integral of the noise
process ζ3(t). In the case of off-treatment periods, (27)
and (29) must be used, so that (9) must be evaluated, for
which knowledge of the integral of the noise process ζ3(t)
is also needed. In the second and third terms in (43), ∆ONm
can be computed using timers whose start and end times
are observable events, while η′m,i and ξ
′
m,i, m = 1, . . . ,MT ,
and eventually ξ′MT+1,i, can be computed through (42),
which requires knowledge of the noise processes ζ1(t) and
ζ2(t) evaluated at event times only.
4. CONCLUSION
Biological systems are inherently sensitive to physiologic
cues, such as the timing and dosage of drugs and related
procedures. Hence, performing sensitivity analysis of the
mathematical models that infer patient response to such
cues will aid the development of personalized treatment
schemes. Such sensitivity analysis should not only allow for
evaluating the sensitivies with respect to model parame-
ters, but also, and most importantly, provide sensitivity
estimates with respect to controllable parameters in a
therapy. The methodology we have laid out in this paper
addresses both these needs.
Indeed, this work is the first step towards the devel-
opment of a methodology for personalized therapy design
applicable to stochastic models of cancer progression. We
illustrate our analysis with a case study of optimal IAS
therapy design for prostate cancer. For such, we propose
an SHA model to describe the evolution of prostate cancer
under IAS therapy and derive a cost metric in terms of
the desired outcome of IAS therapy that is parameterized
by an appropriately chosen controllable parameter vector.
The problem of optimal personalized therapy design is
then formulated as the search for the parameter values
which minimize our cost metric. In this context, we apply
Infinitesimal Perturbation Analysis (IPA) and derive un-
biased gradient estimates of the cost metric with respect
to the controllable vector of interest, which can be used
for sensitivity analysis of therapy schemes.
More importantly, however, since (43) provides an unbi-
ased estimate of dJ(θ)/dθi, it can also be ultimately used
for therapy estimation and optimization. To this end, it
is possible to implement an algorithm for updating the
value of dL(θ)/dθi after each observed event. Such value
can then be used to compute an optimal θ∗ through an
interative optimization procedure of the form θi,l+1 =
θi,l − ρlHi,l (θl, x(0), T, ωl), where ρl is the step size at
the lth iteration, l = 0, 1, . . ., and ωl denotes a sample
path from which data are extracted and used to compute
Hi,l (θl, x(0), T, ωl) defined to be an estimate of dJ(θ)/dθi.
The sample paths can be generated through simulation of
existing models (e.g., our SHA model), so that, by varying
the model parameters, different patient behaviors can be
analyzed. Alternatively, it is possible to apply our IPA
estimators to real patient data obtained from clinical trials
(available e.g., in Bruchovsky et al. (2006) and Bruchovsky
et al. (2007)), and ultimately contrast the optimal therapy
scheme θ∗ with the prescribed one. Our ongoing work
involves implementing the IPA estimators derived in this
work for personalized IAS therapy design.
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